Sean Morony
Overview
Explore the profile of Sean Morony including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
2072
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wehn P, Harrington P, Carlson T, Davis J, Deprez P, Fotsch C, et al.
Bioorg Med Chem Lett
. 2013 Nov;
23(24):6625-8.
PMID: 24215889
A series of urea based calcimimetics was optimized for potency and oral bioavailability. Crucial to this process was overcoming the poor pharmacokinetic properties of lead thiazole 1. Metabolism-guided modifications, characterized...
2.
Henley 3rd C, Yang Y, Davis J, Lu J, Morony S, Fan W, et al.
J Pharmacol Exp Ther
. 2011 Mar;
337(3):681-91.
PMID: 21422163
Calcimimetics are positive allosteric modulators to the calcium-sensing receptor (CaSR). Activation of the CaSR inhibits the secretion of parathyroid hormone (PTH), stimulates the secretion of calcitonin, and decreases serum calcium...
3.
Harrington P, St Jean Jr D, Clarine J, Coulter T, Croghan M, Davenport A, et al.
Bioorg Med Chem Lett
. 2010 Aug;
20(18):5544-7.
PMID: 20708930
The discovery of a series of novel and orally efficacious type II calcimimetics, developed from the lead compound 1, is described herein. Compound 22 suppressed plasma PTH levels relative to...
4.
Poon S, St Jean Jr D, Harrington P, Henley 3rd C, Davis J, Morony S, et al.
J Med Chem
. 2009 Oct;
52(21):6535-8.
PMID: 19835382
Our efforts to discover potent, orally bioavailable type II calcimimetic agents for the treatment of secondary hyperparathyroidism focused on the development of ring constrained analogues of the known calcimimetic R-568....
5.
Babij P, Roudier M, Graves T, Han C, Chhoa M, Li C, et al.
J Bone Miner Res
. 2009 May;
24(9):1552-64.
PMID: 19419305
A large genome-wide, recessive, N-ethyl-N-nitrosourea (ENU)-induced mutagenesis screen was performed on a mixed C57BL/6J and C3H.SW-H2/SnJ mouse background to identify genes regulating bone mass. Approximately 6500 male and female G(3)...
6.
Allen D, Bandstra E, Harrison B, Thorng S, Stodieck L, Kostenuik P, et al.
J Appl Physiol (1985)
. 2008 Dec;
106(2):582-95.
PMID: 19074574
Spaceflight results in a number of adaptations to skeletal muscle, including atrophy and shifts toward faster muscle fiber types. To identify changes in gene expression that may underlie these adaptations,...
7.
Li X, Ominsky M, Warmington K, Morony S, Gong J, Cao J, et al.
J Bone Miner Res
. 2008 Dec;
24(4):578-88.
PMID: 19049336
The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long-standing goal. Genetic studies in humans and mice...
8.
Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N, et al.
J Bone Miner Res
. 2008 Nov;
24(2):182-95.
PMID: 19016581
RANKL is a TNF family member that mediates osteoclast formation, activation, and survival by activating RANK. The proresorptive effects of RANKL are prevented by binding to its soluble inhibitor osteoprotegerin...
9.
Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D, et al.
J Bone Miner Res
. 2008 Feb;
23(6):860-9.
PMID: 18269310
Introduction: Sclerosteosis is a rare high bone mass genetic disorder in humans caused by inactivating mutations in SOST, the gene encoding sclerostin. Based on these data, sclerostin has emerged as...
10.
Morony S, Tintut Y, Zhang Z, Cattley R, Van G, Dwyer D, et al.
Circulation
. 2008 Jan;
117(3):411-20.
PMID: 18172035
Background: The role of osteoprotegerin in vascular disease is unclear. Recent observational studies show that serum osteoprotegerin levels are associated with the severity and progression of coronary artery disease, atherosclerosis,...